Related Experiment Videos
Hemophilia orthopedic management with emphasis on developing countries
E Carlos Rodriguez-Merchan1, Michael Heim
1Haemophilia Centre, La Paz University Hospital, Madrid, Spain.
Seminars in Thrombosis and Hemostasis
|November 9, 2005
Summary
Early prophylaxis is crucial for children with hemophilia to prevent joint damage. Aggressive treatment of hemarthroses and synovitis is vital when prophylaxis isn't possible, preserving joint function.
Area of Science:
- Orthopedics
- Hematology
- Pediatrics
Background:
- Hemophilia commonly causes hemarthroses from infancy, leading to progressive joint damage.
- Immature skeletons are highly susceptible to hemophilia complications, potentially causing severe structural deficiencies.
- Joint problems in hemophilia can lead to synovitis, recurrent bleeds, and end-stage arthritis.
Purpose of the Study:
- To emphasize the importance of early continuous prophylaxis in managing hemophilia-related joint issues.
- To outline aggressive treatment strategies for hemarthroses and synovitis when prophylaxis is not feasible.
- To review treatment options for established articular complications in adult hemophilia patients.
Main Methods:
- Review of current literature and clinical guidelines on hemophilia joint management.
- Analysis of the impact of prophylaxis versus episodic treatment on joint health.
- Description of conservative and operative interventions for synovitis and advanced joint disease.
Main Results:
- Early continuous prophylaxis significantly reduces the risk of severe structural joint deficiencies.
- Aggressive management of hemarthrosis and synovitis can prevent or delay end-stage arthritis.
- Various surgical interventions are available for established articular complications in hemophilia.
Conclusions:
- Prophylaxis from childhood is the cornerstone of preventing hemophilia arthropathy.
- Prompt and effective treatment of joint bleeds and synovitis is essential for long-term joint preservation.
- A range of surgical options exist for managing advanced joint disease in hemophilia patients.